@article{3194275,
    title = "The Impact of Comorbid Diabetes Type 2 on Quality of Life in Cancer
Patients Undergoing Chemotherapy",
    author = "Lavdaniti, Maria and Michalopoulou, Styliani and Owens, Dimitra-Anna and and Vlachou, Eugenia and Kazakos, Kyriakos",
    journal = "Endocrine, Metabolic & Immune Disorders - Drug Targets",
    year = "2021",
    volume = "21",
    number = "6",
    pages = "1017-1024",
    publisher = "BENTHAM SCIENCE PUBL LTD",
    issn = "1871-5303",
    doi = "10.2174/1871530320666200729151715",
    keywords = "Cancer; type 2 diabetes; chemotherapy; quality of life; Greece; factors",
    abstract = "Background and Objective: Cancer and diabetes are two highly prevalent
diseases worldwide and greatly influence quality of life of those
suffering from it. The study aimed to compare quality of life in
patients diagnosed with cancer and diabetes with those without diabetes
both undergoing chemotherapy and to investigate the factors responsible
for the difference between the two groups.
Methods: A convenience sample of 101 participants who had cancer and
type 2 diabetes and 99 who had cancer without diabetes were used.
Results: Patients with comorbid diabetes were divided based on their
diabetes duration and whether they had glycaemic control or not.
Diabetic cancer patients without glycaemic control had lower scores in
global health status and in physical and emotional functioning compared
to diabetic cancer patients with glycaemic control and patients without
diabetes (p < .05). After adjusting for demographic characteristics, the
differences between the group with diabetes and without glycaemic
control and the other two groups regarding global health status were
statistically significant (p < .05). Patients with more than a 7-year
history of diabetes had a significantly lower emotional functioning than
the no diabetes group and lower global health status score than both of
the other groups (p < .05). After adjusting for clinical and demographic
characteristics, only the difference between the >= 7 years diabetes
duration group and the no diabetes groups remained significant.
Conclusion: The presence of diabetes in cancer patients who underwent
chemotherapy seems to negatively influence certain domains of quality of
life and this may be affected by the duration of diabetes and whether
glycaemic control has been achieved or not."
}